外科手术治疗药物相关性颌骨坏死的回顾性研究

doi:10.13701/j.cnki.kqyxyj.2026.01.005

口腔医学研究 ›› 2026, Vol. 42 ›› Issue (1): 22-29.DOI: 10.13701/j.cnki.kqyxyj.2026.01.005

外科手术治疗药物相关性颌骨坏死的回顾性研究

王睿, 李馥焰, 何金媛, 孙国文^*

南京大学医学院附属口腔医院·南京市口腔医院口腔颌面头颈肿瘤外科南京大学口腔医学研究所江苏南京 210008

收稿日期:2025-05-29 出版日期:2026-01-28 发布日期:2026-01-23
通讯作者: *孙国文,E-mail:238957@sina.com
作者简介:王睿(1999~ ),男,江苏盐城人,硕士,研究方向:口腔颌面外科。
基金资助:
南京市卫生科技发展专项资金项目(编号:YKK22183)

Retrospective Study on Surgical Treatment of Medication-related Osteonecrosis of The Jaw

WANG Rui, LI Fuyan, HE Jinyuan, SUN Guowen^*

Department of Oral and Maxillofacial Head and Neck Oncology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing 210008, China

Received:2025-05-29 Online:2026-01-28 Published:2026-01-23

摘要/Abstract

摘要： 目的: 总结分析接受手术治疗的药物相关性颌骨坏死(medication-related osteonecrosis of the jaw, MRONJ)患者的临床资料,探讨手术方式等对疾病预后的影响。方法: 回顾性分析2013年1月~2024年10月南京市口腔医院收治的173例2~3期MRONJ手术患者资料,采用χ²检验和Fisher精确检验比较不同分组及手术方式的预后差异。结果: 总计144例治愈,29例复发,总治愈率为83.2%,下颌骨治愈率显著低于上颌骨(P<0.05)。骨管技术(难治型2期)和钛板修复(下颌3期)显著提高治愈率(P<0.05),而上颌3期开窗引流与次全切除术患者预后无差异(P>0.05)。结论: MRONJ发病无明显性别差异,下颌骨较上颌骨手术预后差,骨管技术与重建钛板修复是改善预后的关键。

关键词: 药物相关性颌骨坏死, 手术治疗, 预后, 骨管技术

Abstract: Objective: To summarize and analyze the clinical data of patients with medication-related osteonecrosis of the jaw (MRONJ) who underwent surgical treatment and to explore the impact of surgical methods and other factors on disease prognosis. Methods: A retrospective analysis was conducted on the data of 173 patients with stage 2-3 MRONJ who underwent surgery at Nanjing Stomatological Hospital from January 2013 to October 2024. Results: A total of 144 cases were cured and 29 cases relapsed. The overall cure rate was 83.2%, and the cure rate of the mandible was significantly lower than that of the maxilla (P<0.05). Bone tube technique (for refractory stage 2) and titanium plate reconstruction (for stage 3 mandible) significantly improved the cure rate (P<0.05), while there was no significant difference in prognosis for stage 3 maxilla with window drainage and subtotal resection (P>0.05). Conclusion: There is no significant gender difference in the incidence of MRONJ. The prognosis of surgery for mandibular MRONJ is worse than that for maxillary MRONJ. Bone tube technique and titanium plate reconstruction are key to improving prognosis.

Key words: medication-related osteonecrosis of the jaw, surgical treatment, prognosis, bone canal technique

王睿, 李馥焰, 何金媛, 孙国文. 外科手术治疗药物相关性颌骨坏死的回顾性研究[J]. 口腔医学研究, 2026, 42(1): 22-29.

WANG Rui, LI Fuyan, HE Jinyuan, SUN Guowen. Retrospective Study on Surgical Treatment of Medication-related Osteonecrosis of The Jaw[J]. Journal of Oral Science Research, 2026, 42(1): 22-29.

参考文献

[1] Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9):1115-1117.
[2] Ruggiero SL, Dodson TB, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2022 update[J]. J Oral Maxillofac Surg, 2022, 80(5):920-943.
[3] 刘忠龙,姜钧健,李晓光,等.一种新的药物性颌骨坏死临床分期及治疗策略[J].中国口腔颌面外科杂志,2020,18(6):501-507.
[4] 郭玉兴,王佃灿,刘筱菁,等.翻瓣联合骨管技术拔牙方案在药物相关性颌骨坏死潜在风险患者中的应用初探[J].中华口腔医学杂志,2021,56(5):452-457.
[5] 田美,王丹妮,罗舒艳,等.上颌骨药物相关性颌骨坏死的手术治疗效果初探[J].中华口腔医学杂志,2021,56(5):447-451.
[6] 何悦,陈珩,安金刚,等.药物相关性颌骨坏死临床诊疗专家共识[J].中国口腔颌面外科杂志,2023,21(4):313-325.
[7] Shin JW, Kim JE, Huh KH, et al. Computed tomography imaging features of osteomyelitis of the jaw: comparison between antiresorptive medication-related conditions and medication-unrelated conditions[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2020, 129(6):629-634.
[8] 高娜,田美,孙亚威,等.骨管技术在Ⅱ期下颌骨药物相关性颌骨坏死手术中的应用初探[J].华西口腔医学杂志,2024,42(5):629-635.
[9] Russmueller G, Seemann R, Weiss K, et al. The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection[J]. Sci Rep, 2016, 6:31604.
[10] Mu Y, Feiwu K, Xueming Z. Research progress on the at-risk category and stage 0 of medication-related osteonecrosis of the jaw[J]. J Oral Maxillofac Surg, 2025, 35:53.
[11] Park JH, Park W, Nguyen LP, et al. Treatment period and changes in bone markers according to the application of teriparatide in treating medication-r-elated osteonecrosis of the jaw[J]. BMC Oral Health, 2025, 25(1):528.
[12] 肖维维,陈媛丽,宗春琳,等.己酮可可碱和维生素E联合治疗放射性颌骨骨坏死的Meta分析[J]. 中华口腔医学研究杂志(电子版),2017,11(4):218-224.
[13] Otto S, Ristow O, Pache C, et al. Fluorescave-guided surgery for the treatment of medication-related ostenecrosis of the jaw: A prospective cohort study[J]. J Cranio-maxillofac Surg, 2016,44(8):1073-1080.
[14] Yoshiga D, Sasaguri M, Matsuo K, et al. Intraoperative detection of viable bone with fluorescence imaging using Visually Enhanced Lesion Scope in patients with bisphosphonate-related osteonecrosis of the jaw: clinical and pathological evaluation[J]. Osteoporos Int, 2015, 26(7):1997-2006.
[15] 郭玉兴,张建运,王佃灿,等.药物相关颌骨骨坏死的病理特点及临床治疗策略[J].北京大学学报(医学版),2022, 54(6):1190-1195.
[16] 周颖,赵宁,黄骇远,等.双层软组织缝合封闭技术在下颌骨中早期药物相关性颌骨骨坏死患者手术治疗中的应用[J].北京大学学报(医学版),2024, 56(1):51-56.
[17] 孙国文,田美.药物相关性颌骨坏死不同阶段治疗方法述评[J].口腔颌面外科杂志,2022,32(3):135-143.

外科手术治疗药物相关性颌骨坏死的回顾性研究

Retrospective Study on Surgical Treatment of Medication-related Osteonecrosis of The Jaw

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	周春香, 曹正国, 张慧慧. 露龈笑美学牙冠延长术1例[J]. 口腔医学研究, 2025, 41(9): 824-828.
[2]	王睿, 何金媛, 蒲玉梅, 陈欣, 孙国文. D-二聚体对手术治疗药物相关性颌骨坏死患者预后价值的研究[J]. 口腔医学研究, 2025, 41(7): 568-573.
[3]	史婷婷, 李晨曦, 龚忠诚, 崔文丽, 买买提吐逊·吐尔地, 张维娜. 317例老年口咽癌患者的临床特征和预后分析:一项单中心15年回顾性研究[J]. 口腔医学研究, 2025, 41(2): 101-108.
[4]	刘絮影, 李锦存, 翟堃, 胡晨, 董文, 马坚. 口腔鳞状细胞癌预后相关的长链非编码RNA筛选及验证[J]. 口腔医学研究, 2025, 41(2): 109-117.
[5]	胡泽龙, 李培博, 谢雨翀, 李冉, 李冰炎, 李锐. 高负压引流瓶在颌面部肿物切除术后应用的回顾性研究[J]. 口腔医学研究, 2024, 40(9): 793-796.
[6]	刘家琦, 梁登桓, 张佳佳, 郭超杰, 刘昱词, 徐江, 曾妍, 郑军. COL7A1和LAMC2在口腔鳞状细胞癌中的表达及预后意义[J]. 口腔医学研究, 2024, 40(7): 634-639.
[7]	梁登桓, 刘家琦, 李东慧, 张佳佳, 郭超杰, 曾妍, 徐江, 郑军. 头颈部鳞状细胞癌中USP10的表达及其预后价值[J]. 口腔医学研究, 2024, 40(5): 417-421.
[8]	卢芳, 宁彤彤, 王婕, 赵嘉, 房静, 宁倩倩, 李家锋. MYO5A 35号外显子跳跃对头颈鳞状细胞癌患者的预后相关研究[J]. 口腔医学研究, 2024, 40(3): 236-241.
[9]	房敏健, 刘亮, 邱若兰, 曹伟, 葛素云, 柴大敏. 肿瘤间质比在口腔鳞状细胞癌患者预后评估中的价值分析[J]. 口腔医学研究, 2024, 40(3): 242-247.
[10]	苏传超, 林梓桐, 王靖斐, 顾镇, 薛逸文, 邓润智. 药物相关性颌骨坏死对比化脓性颌骨骨髓炎影像学及临床特点的研究[J]. 口腔医学研究, 2024, 40(12): 1065-1070.
[11]	宝鲁日, 施琳. 影响涎腺导管癌预后的临床病理因素和免疫组化标记物[J]. 口腔医学研究, 2024, 40(11): 1013-1018.
[12]	唐燕驰, 葛殿奎. 牙龈外周性骨化性纤维瘤1例[J]. 口腔医学研究, 2024, 40(11): 1025-1027.
[13]	马英娟, 李晨曦, 王玥, 龚忠诚. 196例颈深部感染患者临床特征分析:一项多中心15年回顾性研究[J]. 口腔医学研究, 2024, 40(10): 878-884.
[14]	陈河林, 舒佳玉, 董强. CENPN对头颈鳞状细胞癌患者预后的预测价值研究[J]. 口腔医学研究, 2023, 39(8): 690-695.
[15]	杨可, 孙雅楠, 胡雅英, 吕宜楠, 郑小风, 李易玮, 张佳莉. cyclin D1表达模式深度学习识别和预测模型对HPV阴性口腔鳞状细胞癌和口咽鳞状细胞癌患者预后的预测作用[J]. 口腔医学研究, 2023, 39(4): 308-315.